Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 5:20 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2113–2136 of 3,875 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: fast Clear all

Conditions: Localized Prostate Carcinoma, Locally Advanced Cervical Carcinoma, Locally Advanced Rectal Carcinoma, Malignant Solid Neoplasm, Recurrent Prostate Carcinoma, Stage I Prostate Cancer AJCC v8, Stage IB Cervical Cancer FIGO 2018, Stage IB2 Cervical Cancer FIGO 2018, Stage II Prostate Cancer AJCC v8, Stage II Rectal Cancer AJCC v8, Stage IIA Cervical Cancer FIGO 2018, Stage IIB Cervical Cancer FIGO 2018, Stage III Prostate Cancer AJCC v8, Stage III Rectal Cancer AJCC v8, Stage IIIA Cervical Cancer FIGO 2018, Stage IIIB Cervical Cancer FIGO 2018, Stage IIIC Cervical Cancer FIGO 2018, Stage IVA Prostate Cancer AJCC v8
Interventions: Biospecimen Collection, Informational Intervention, Quality-of-Life Assessment, Questionnaire Administration, Short-Term Fasting; Procedure · Other · Behavioral
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Duarte, California

Conditions: Hypertension
Interventions: Irbesartan, Avapro; Drug
Lead sponsor: Roxane Laboratories; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Inflammatory Bowel Diseases
Interventions: ECG recording, inflammatory cytokines, microbiota, ulcerative colitis disease activity index; Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Pain
Interventions: Test fentanyl citrate 400 mcg troche, Actiq 400 mcg; Drug
Lead sponsor: Mallinckrodt; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Chronic Stroke
Interventions: Virtual reality based dance group, Active Comparator: Control; Behavioral
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 45 Years to 90 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Cardiac Arrest
Interventions: RapidShock; Device
Lead sponsor: Zoll Medical Corporation; Industry
Eligibility: 8 Years and older
Enrollment: 2,756 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 7
States / cities: Camarillo, California • Colorado Springs, Colorado • Baton Rouge, Louisiana + 4 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Macrolide Antibiotic (Azithromycin), Placebo; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 40 Years and older
Enrollment: 1,142 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 10
States / cities: Birmingham, Alabama • San Francisco, California • Torrance, California + 7 more

Conditions: Healthy
Interventions: Alprazolam 3 mg Extended Release Tablets, single dose, XANAX XR® 3 mg tablets, single dose; Drug
Lead sponsor: Actavis Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Fanconi Anemia
Interventions: Bone Marrow Aspiration, Filgrastim, Genetically Engineered Hematopoietic Stem Progenitor Cells, Laboratory Biomarker Analysis, Leukapheresis, Methylprednisolone, Plerixafor, Prednisone; Procedure · Biological · Other + 1 more
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 4 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2024
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Anemia
Interventions: Erythropoietin alpha, Placebo; Drug
Lead sponsor: Mathew S. Maurer; Other
Eligibility: 55 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: New York, New York

Conditions: Diabetes Mellitus
Interventions: Degludec, Standard long-acting; Drug
Lead sponsor: Hennepin Healthcare Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Other Constipation, Irritable Bowel Syndrome
Interventions: Lubiprostone; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 75 Years
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Type1diabetes
Interventions: Mixed Meal Tolerance Test; Other
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 5 Years to 17 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Pre-Diabetes
Interventions: Aerobic Exercise, Exercise and Diet; Behavioral
Lead sponsor: Duke University; Other
Eligibility: 45 Years to 75 Years
Enrollment: 288 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Prostatic Neoplasms, Genital Neoplasms, Male, Genital Diseases, Male, Prostatic Diseases
Interventions: EPI-506; Drug
Lead sponsor: ESSA Pharmaceuticals; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 4
States / cities: Scottsdale, Arizona • Ann Arbor, Michigan • Detroit, Michigan + 1 more

Conditions: Opioid Overdose
Interventions: Opioid Rapid Resonse System (ORRS) training, Non-active opioid overdose response training; Behavioral
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 18 Years to 100 Years
Enrollment: 773 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Food Choices
Interventions: Control (QR) Labels, Low Sustainability Labels, Unsustainable Labels, Environmental Harm Labels, High Environmental Harm Labels, High Environmental Cost Labels, Numeric Environmental Cost Labels; Behavioral
Lead sponsor: Johns Hopkins Bloomberg School of Public Health; Other
Eligibility: 18 Years and older
Enrollment: 14,720 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: PTSD - Post Traumatic Stress Disorder, Cognitive Dysfunction, Brain Trauma, Brain Injuries
Interventions: Hormone Replacement Therapy (HRT), Magnetic Resonance Therapy (MeRT), ibogaine with magnesium treatment, 5-MeO-DMT; Other · Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy Volunteers
Interventions: Evacetrapib, High-fat Meal; Drug · Other
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Daytona Beach, Florida

Conditions: Relative Bioavailability, AUC, Cmax, Pharmacokinetics
Interventions: D1400147, D14000136, D14000137, Epanova®; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 137 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Alcoholism
Interventions: Perampanel, Placebo; Drug
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 21 Years to 70 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 4
States / cities: Farmington, Connecticut • New Haven, Connecticut • West Haven, Connecticut + 1 more

Conditions: Breast Cancer, Early-stage Breast Cancer
Interventions: Fasting; Behavioral
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Body Weight Changes, Human Immunodeficiency Virus, ART, Obesity, Minority Health, BMD, Metabolic Syndrome, Fasting
Interventions: DOR/3TC/TDF, DOR + FTC/TAF, BIC/FTC/TAF; Drug · Combination Product
Lead sponsor: Prism Health North Texas; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Impaired Glucose Tolerance
Interventions: Sildenafil, Placebo, Hyperglycemic clamp, Euglycemic clamp; Drug · Diagnostic Test
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Nashville, Tennessee

Search by objective public record fields.

Time-Restricted Eating Versus Nutritional Counseling for the Reduction of Radiation or Chemoradiation Tx Side Effects in Patients With Prostate, Cervical, or Rectal Cancers

Crossover Bioequivalence Study of Irbesartan 300 mg Tablets Under Fasted Conditions

Autonomic and Cytokines Profiles of Patients With Ulcerative Proctitis

Bioequivalence of a Test Troche Formulation of Fentanyl Citrate (400 mcg) Compared to Actiq® 400 mcg, Cephalon, Inc.

Active Balance and Cardio Care Intervention on Physical and Cardiovascular Health in People With Chronic Stroke

RapidShock Post-Approval Study

Macrolide Azithromycin to Prevent Rapid Worsening of Symptoms Associated With Chronic Obstructive Pulmonary Disease

A Relative Bioavailability Study of Alprazolam 3 mg ER Tablets Under Fasting Conditions

Gene Therapy for Fanconi Anemia

Anemia in Heart Failure With a Preserved Ejection Fraction (HFPEF)

Insulin Degludec for the Management of Patient With Recurrent Diabetic Ketoacidosis

Intestinal Microecology in Chronic Constipation

Development of Predictive Biomarkers

Exercise Dose-Response Effects in Prediabetes

Safety and Anti-Tumor Study of Oral EPI-506 for Patients With Metastatic Castration-Resistant Prostate Cancer

Opioid Rapid Response System: Naloxone Training in Communities

Perceptions of and Reactions to Sustainability Menu Label Designs

Trifecta Research Study

Study of Food on Evacetrapib (LY2484595) in Healthy Participants

Study in Healthy Subjects to Compare the Concentrations of the Omega-3 Fatty Acids EPA and DHA in Blood When Delivered as Three New Capsules in Relation to the Epanova® Capsule Under Fasting and Fed Conditions

Rapid Determination Of The Clinical Utility Of Perampanel For The Treatment Of Alcohol Dependence

Gut Microbiome, Adverse Effects, and Markers Through MEtabolic Reprogramming

Doravirine and Weight Gain in Antiretroviral Naive

Renin-Angiotensin and Fibrinolysis in Humans: Effect of Long-Term PDE5 Inhibition on Glucose Homeostasis